Finally, durvalumab, an anti-PDL1 human antibody, is approved as consolidation therapy for patients with unresectable stage III NSCLC who have not progressed after 2 or more cycles of definitive concurrent platinum-based chemoradiation10. The gene discussed is CD274; the disease is non-small cell lung carcinoma.